Live attenuated vaccines against influenza; an historical review

Vaccine

Volumn 19, Issue 25-26, 2001, Pages 3320-3330

  Wareing, M D ^a   Tannock, G A ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

Development; Influenza; Live vaccines

Indexed keywords

LIVE VACCINE;

ADULT; CHILD; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFANT; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; PRIORITY JOURNAL; REVIEW; VIRUS MUTANT; VIRUS VIRULENCE;

ADULT; AGED; ANIMALS; CHILD; HISTORY, 20TH CENTURY; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; SPECIES SPECIFICITY; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SYNTHETIC;

EID: 0035858117     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00045-7     Document Type: Review

References (93)

1. Immunization for the prevention of influenza
2. High growth reassortant influenza vaccine viruses: New approaches to their control
3. Orthomyxoviruses
4. Morphological and biochemical characterisation of influenza vaccines commercially available in the United Kingdom
5. Attenuated influenza virus vaccines
6. Prevention and control of influenza: Part 1, vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
7. A randomised controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease
8. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection
9. Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin
10. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine
11. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus
12. The immune response to influenza infection
13. Influenza virus clearance in B lymphocyte deficient mice
14. Orthomyxoviruses
15. Temperature-sensitive mutants of influenza virus. II. Attenuation of ts recombinants for man
16. Attenuation of human influenza A viruses
17. Recombinant WRL 105 strain live attenuated influenza vaccine
18. Evaluation of avian-human reassortant influenza A/Washington/897/80 × A/Pintail/119/79 virus in monkeys and adult volunteers
19. Obtaining of an additionally attenuated vaccinating cryophil influenza strain
20. Adaptation and growth characteristics of influenza virus at 25°C
21. Development of novel influenza virus vaccines and vectors
22. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection
23. Temperature-sensitive mutants of influenza virus. I. Behaviour in tissue culture and in experimental animals
24. Live attenuated influenza vaccines in young seronegative children
25. Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo
26. 2 influenza viruses
27. 2)
28. Procedures for characterisation of the genetic material of candidate vaccine strains
29. Research into the immunisation of humans against influenza by means of live viruses
30. Gene constellation of live influenza A vaccines
31. Comparison of the virologic and immunologic responses of volunteers to live avian-human influenza A H3N2 reassortant virus vaccines derived from 2 different avian influenza virus donors
32. Comparison of live attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults
33. The avian influenza virus nucleoprotein gene and a specific constellation of avian and human virus polymerase genes each specify attenuation of avian-human influenza A/Pintail/79 reassortant viruses for monkeys
34. Characterisation of the attenuating M and NP gene segments of the avian influenza A/Mallard/78 virus during in vitro production of avian-human reassortant vaccine viruses and after replication in humans and primates
35. Live attenuated influenza vaccines
36. Reverse genetics of negative strand RNA viruses: Closing the circle
37. Genetically engineered live attenuated influenza A virus vaccine candidates
38. RNA polymerase I-mediated expression of influenza viral RNA molecules
39. Generation of influenza A viruses entirely from cloned cDNAs
40. Rescue of influenza A virus from recombinant DNA
41. 'Ambisense' approach for the generation of influenza A viruses: vRNA and mRNA synthesis from one template
42. Live attenuated vaccines against influenza
43. Synthetic recombinant vaccines against viral agents
44. Enteric immunisation of mice against influenza with recombinant vaccinia
45. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus
46. Comparison of antigen presentation of influenza A nucleoprotein expressed in attenuated AroA-Salmonella typhimurium with that of live virus
47. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge
48. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malarial parasite or of influenza virus elicit protection against the corresponding pathogen in mice
49. Genetic stability of cold-adapted A/Leningrad/134/47/57 (H2N2) influenza virus: Sequence analysis of live cold-adapted reassortant vaccine strains before and after replication in children
50. Sequence changes in the live attenuated, cold-adapted variants of influenza A/Leningrad/134/57 (H2N2) virus
51. Molecular and biological changes in the cold-adapted 'master strain' A/AA/6/60 (H2N2) influenza virus
52. Sequence comparisons of A/AA/6/60 influenza viruses: Mutations which may contribute to attenuation
53. Biologic and immunologic characteristics of cold-adapted influenza virus
54. Development of cold-adapted recombinant live, attenuated influenza vaccines in the USA and USSR
55. Recombinants of cold-adapted attenuated influenza A vaccines for use in children: Molecular and genetic analysis of the cold-adapted donor and recombinants
56. Identification of sequence changes in the cold-adapted, live attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2)
57. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines
58. Analysis of genome composition and reactogenicity of recombinants of cold-adapted and virulent virus strains
59. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial
60. Cold-adapted live attenuated influenza vaccines developed in Russia: Can they contribute to meeting the needs for influenza control in other countries?
61. Development and characterization of cold-adapted viruses for use as live vaccines
62. Evaluation of cold-adapted reassortant influenza B virus vaccine in elderly and chronically ill patients
63. Variability in infectivity of cold-adapted recombinant influenza virus vaccines in humans
64. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: Role of local antibody in resistance to infection with vaccine virus
65. Dose response of influenza A/Washington/897/80 (H3N2) cold-adapted reassortant virus in adult volunteers
66. Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers
67. Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults
68. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly
69. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults
70. Live attenuated influenza A virus vaccines in children: Results of a field trial
71. Effective immunisation with live attenuated influenza A virus can be achieved in early infancy
72. Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: Safety, immunogenicity and dose-response
73. Trials of influenza A/New Jersey/76 virus vaccine in normal children: An overview of age-related antigenicity and reactogenicity
74. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren
75. A review of attenuation of influenza viruses by genetic manipulation
76. Interference following dual inoculation with influenza A (H3N2) and (H1N1) viruses in ferrets and volunteers
77. Protective responses in mice to vaccination with multiply administered cold-adapted influenza vaccine reassortants and wild-type viruses
78. Comparison of monovalent and trivalent live attenuated influenza vaccines in young children
79. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent virus (TI) vaccines in infants and young children
80. Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine
81. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children
82. Cold-adapted recombinant influenza A virus vaccines in seronegative young children
83. Advances in influenza virus research
84. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children
85. Estimation of the efficacy of live, attenuated influenza vaccine from a 2-year, multi-center vaccine trial: Implications for influenza epidemic control
86. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: Safety, immunogenicity, and efficacy
87. Study of live recombinant ca influenza bivalent vaccine of type A for use in children: An epidemiological control trial
88. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3-14-year-olds
89. Infectivity and reactogenicity of reassortant cold-adapted influenza A/Korea/1/82 vaccines obtained from the USA and USSR
90. Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza A vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57 and A/Ann Arbor/6/60 (H2N2) in mice
91. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses
92. Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects
93. Safety and immunogenicity of Russian live attenuated and US inactivated trivalent vaccines in the elderly